Switch maintenance therapy for advanced bladder cancer: A paradigm shift in 2020

Cancer Treat Res Commun. 2020:24:100202. doi: 10.1016/j.ctarc.2020.100202. Epub 2020 Jul 31.

Authors

Neal S Chawla¹, Jasnoor Malhotra¹, Sumanta K Pal²

Affiliations

¹ Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
² Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.

PMID: 32805533
DOI: 10.1016/j.ctarc.2020.100202

No abstract available

Keywords: Avelumab; Bladder cancer; Immunotherapy; Pembrolizumab; Switch maintenance.

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Immunoconjugates / therapeutic use*
Maintenance Chemotherapy / methods*
Maintenance Chemotherapy / trends
Molecular Targeted Therapy / trends
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Progression-Free Survival
Randomized Controlled Trials as Topic
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / genetics
Urinary Bladder Neoplasms / immunology
Urinary Bladder Neoplasms / mortality

Substances

Antineoplastic Agents, Immunological
Immunoconjugates
Poly(ADP-ribose) Polymerase Inhibitors